Browse OBSCN

Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 3: Cytoplasm, myofibril, sarcomere, M line Cytoplasm, myofibril, sarcomere, Z line Note=In differentiating skeletal muscle cells, isoform 3 primarily localizes to the sarcomeric M-line and less frequently to the Z-disk (PubMed:12527750). Isoform 3 colocalizes with ANK1 isoform Mu17/ank1.5 at the M-line in differentiated skeletal muscle cells (PubMed:12527750).; SUBCELLULAR LOCATION: Cytoplasm, myofibril, sarcomere, M line Cytoplasm, myofibril, sarcomere, Z line Cell membrane, sarcolemma Nucleus Note=Colocalizes with CDH2 and ATP1B1 to the sarcolemma and to intercalating disks in cardiac muscles. Colocalizes with ATP1B1 to M line and Z line in cardiac muscles.
Domain PF00041 Fibronectin type III domain
PF07679 Immunoglobulin I-set domain
PF00612 IQ calmodulin-binding motif
PF00069 Protein kinase domain
PF00621 RhoGEF domain
Function

Structural component of striated muscles which plays a role in myofibrillogenesis. Probably involved in the assembly of myosin into sarcomeric A bands in striated muscle (PubMed:11448995, PubMed:16205939). Has serine/threonine protein kinase activity and phosphorylates N-cadherin CDH2 and sodium/potassium-transporting ATPase subunit ATP1B1 (By similarity).

> Gene Ontology
 
Biological Process GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0010927 cellular component assembly involved in morphogenesis
GO:0030239 myofibril assembly
GO:0031032 actomyosin structure organization
GO:0035023 regulation of Rho protein signal transduction
GO:0036309 protein localization to M-band
GO:0042692 muscle cell differentiation
GO:0045214 sarcomere organization
GO:0046578 regulation of Ras protein signal transduction
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051146 striated muscle cell differentiation
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0005085 guanyl-nucleotide exchange factor activity
GO:0005088 Ras guanyl-nucleotide exchange factor activity
GO:0005089 Rho guanyl-nucleotide exchange factor activity
GO:0005516 calmodulin binding
GO:0008307 structural constituent of muscle
GO:0030506 ankyrin binding
GO:0031432 titin binding
Cellular Component GO:0030016 myofibril
GO:0030017 sarcomere
GO:0030018 Z disc
GO:0031430 M band
GO:0031672 A band
GO:0031674 I band
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE
R-HSA-416482: G alpha (12/13) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-193648: NRAGE signals death through JNK
R-HSA-194840: Rho GTPase cycle
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-194315: Signaling by Rho GTPases
R-HSA-166520: Signalling by NGF
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OBSCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OBSCN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OBSCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1660.633
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2890.0166
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6420.223
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1540.701
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0350.991
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3050.938
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2720.576
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7410.558
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1530.906
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1420.921
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2140.91
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6370.000109
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OBSCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141742.911.831.10.0971
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1034033.36.71
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414507.142.90.108
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.220.51.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.225.4-3.21
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211742.935.37.60.744
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)865033.316.70.627
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.536.42.11
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.318.814.50.63
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592033.3-13.31
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 382731.625.95.70.783
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.723.1-0.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161443.828.615.20.466
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OBSCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OBSCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OBSCN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OBSCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OBSCN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OBSCN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOBSCN
Nameobscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
Aliases KIAA1556; UNC89; KIAA1639; ARHGEF30; obscurin, myosin light chain kinase; obscurin-MLCK; Obscurin-myosin lig ......
Chromosomal Location1q42
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OBSCN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.